The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index; 8 of the 18 sources its claims cite were checked for support.
Teclistamab in Relapsed or Refractory Multiple Myeloma
Open accessAbstract
BACKGROUND: Teclistamab is a T-cell-redirecting bispecific antibody that targets both CD3 expressed on the surface of T cells and B-cell maturation antigen expressed on the surface of myeloma cells. In the phase 1 dose-defining portion of the study, teclistamab showed promising efficacy in patients with relapsed or refractory multiple myeloma. METHODS: In this phase 1-2 study, we enrolled patients who had relapsed or refractory myeloma after at least three therapy lines, including triple-class exposure to an immunomodulatory drug, a proteasome inhibitor, and an anti-CD38 antibody. Patients received a weekly subcutaneous injection of teclistamab (at a dose of 1.5 mg per kilogram of body weight) after receiving step-up doses of 0.06 mg and 0.3 mg per kilogram. The primary end point was the overall response (partial response or better). RESULTS: Among 165 patients who received teclistamab, 77.6% had triple-class refractory disease (median, five previous therapy lines). With a median follow-up of 14.1 months, the overall response rate was 63.0%, with 65 patients (39.4%) having a complete response or better. A total of 44 patients (26.7%) were found to have no minimal residual disease (MRD); the MRD-negativity rate among the patients with a complete response or better was 46%. The median duration of response was 18.4 months (95% confidence interval [CI], 14.9 to not estimable). The median duration of progression-free survival was 11.3 months (95% CI, 8.8 to 17.1). Common adverse events included cytokine release syndrome (in 72.1% of the patients; grade 3, 0.6%; no grade 4), neutropenia (in 70.9%; grade 3 or 4, 64.2%), anemia (in 52.1%; grade 3 or 4, 37.0%), and thrombocytopenia (in 40.0%; grade 3 or 4, 21.2%). Infections were frequent (in 76.4%; grade 3 or 4, 44.8%). Neurotoxic events occurred in 24 patients (14.5%), including immune effector cell-associated neurotoxicity syndrome in 5 patients (3.0%; all grade 1 or 2). CONCLUSIONS: Teclistamab resulted in a high rate of deep and durable response in patients with triple-class-exposed relapsed or refractory multiple myeloma. Cytopenias and infections were common; toxic effects that were consistent with T-cell redirection were mostly grade 1 or 2. (Funded by Janssen Research and Development; MajesTEC-1 ClinicalTrials.gov numbers, NCT03145181 and NCT04557098.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
8 of 18 cited sources checked · 5 supported · 0 flagged · accuracy not yet measured
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“In contrast, higher-grade cytokine release syndrome and neurotoxic events have been described after CAR-T administration in patients with multiple myeloma.6,8”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > DISCUSSION
What the sources say
- Supportedcites [6] source
Table 2 reports grade 3 or higher cytokine release syndrome in 7 of 128 patients and grade 3 neurotoxic effects in 4 of 128 after ide-cel infusion. The Methods identify the treated population as patients with relapsed and refractory multiple myeloma. (LLM, conf=0.93)
- Not checked — no full text of the sourcecites [8] source
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passes- Supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Among 165 patients who received teclistamab, 77.6% had triple-class refractory disease (median, five previous therapy lines).”
- Also stated in: § PATIENTS · plain
“Before study entry, 148 patients (89.7%) had resistance to the previous line of therapy, 128 (77.6%) had triple-class refractory disease, and 50 (30.3%) had penta-drug refractory disease.”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > Abstract > RESULTS
Strength:plain· not yet calibratedn = 165Tests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passes- Also stated in: § PATIENTS · plain
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Responses occurred in 104 of 165 patients (63.0%; 95% confidence interval [CI], 55.2 to 70.4).”
- Also stated in: § RESULTS · plain
“the overall response rate was 63.0%”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > RESULTS > EFFICACY
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passes- Also stated in: § RESULTS · plain
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The median duration of progression-free survival was 11.3 months (95% CI, 8.8 to 17.1)”
- Also stated in: § RESULTS · plain
“The median duration of progression-free survival was 11.3 months (95% CI, 8.8 to 17.1).”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > Abstract > RESULTS
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passes- Also stated in: § RESULTS · plain
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The Kaplan–Meier estimate of maintenance of response for at least 12 months was 68.5% (95% CI, 57.7 to 77.1).”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > RESULTS > EFFICACY
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesA result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Otherwise, response rates were consistent across most clinically relevant subgroups, including patients with high-risk cytogenetic abnormalities and those with penta-drug refractory disease (Fig. S2).”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > RESULTS > EFFICACY
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesA result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Hypogammaglobulinemia occurred in 123 patients (74.5%) as determined by means of adverse-event reporting, laboratory analyses (IgG level, <500 mg per deciliter), or both”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > RESULTS > SAFETY
Strength:plain· not yet calibratedn = 123Tests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesA result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Among the 65 patients who had a complete response or better, 30 (46%) had no minimal residual disease (Table S4).”
- Also stated in: § RESULTS · plain
“the MRD-negativity rate among the patients with a complete response or better was 46%”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > RESULTS > EFFICACY
Strength:plain· not yet calibratedn = 65Tests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passes- Also stated in: § RESULTS · plain
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Negativity for minimal residual disease (at a threshold of 10−5) was reported in 44 patients (26.7%; 95% CI, 20.1 to 34.1).”
- Also stated in: § RESULTS · plain
“A total of 44 patients (26.7%) were found to have no minimal residual disease (MRD)”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > RESULTS > EFFICACY
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passes- Also stated in: § RESULTS · plain
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“a complete response or better occurred in 65 (39.4%)”
- Also stated in: § RESULTS · plain
“65 patients (39.4%) having a complete response or better”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > RESULTS > EFFICACY
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passes- Also stated in: § RESULTS · plain
- It may state two separate claims as one. 31
- Probably not a substantial claim. 12
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“CAR-T therapy requires that patients have access to specialized care centers and can wait the minimum 4-week period for production, which can result in attrition rates of approximately 10 to 15%,6-8”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > DISCUSSION
What the sources say
- Partly supportedcites [6] sourceExperimental — accuracy not yet measured
The Patients section (page not available) reports that 12 of 140 enrolled patients discontinued before ide-cel infusion, an attrition rate of about 8.6%, and that some patients received bridging therapy during manufacturing. It does not establish a minimum four-week production period, a requirement for access to specialized care centers, or that waiting caused the discontinuations. (LLM, conf=0.85)
- Partly supportedcites [7] sourceExperimental — accuracy not yet measured
The Discussion and future perspectives section (page unavailable) says CAR T-cell treatment involves a specialized center and that manufacturing takes several days to weeks, during which disease may progress. It does not establish a minimum four-week production period or an attrition rate of approximately 10–15%. (LLM, conf=0.88)
- Not checked — no full text of the sourcecites [8] source
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
- Partly supported
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“Such absence of minimal residual disease has been associated with improved overall survival and progression-free survival in patients with myeloma.14-16”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > DISCUSSION
What the sources say
- Not checked — no full text of the sourcecites [14] source
- Supportedcites [15] source
The Introduction states that MRD-negative status is associated with improved progression-free survival (PFS) and overall survival (OS). The Discussion likewise reports prior multiple-myeloma findings for both outcomes; the paper's own OS data were immature, but the claim does not attribute an OS result to this study's analysis. (LLM, conf=0.94)
- Supportedcites [16] source
The Discussion states that MRD negativity is associated with improved survival in both newly diagnosed and relapsed/refractory myeloma. The Introduction links MRD negativity with prolonged progression-free and overall survival, supporting both endpoints in the claim. (LLM, conf=0.90)
Strength:plain· not yet calibratedCausal:correlational· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
Every source the paper cites for this claim was checked and supports it.
In the paper
“Adverse events were graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (version 4.03), except for cytokine release syndrome (Table S2) and immune effector cell–associated neurotoxicity syndrome, which were graded according to the criteria of the American Society for Transplantation and Cellular Therapy.12”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > METHODS > END POINTS AND ASSESSMENTS
What the sources say
- Supportedcites [12] source
The citation supports the exception for CRS and ICANS: the paper sets out consensus grading criteria for both in its ‘Consensus on CRS Grading (Table 2)’ and ‘Consensus on ICANS Grading for Adults’ sections (page not available). The citing study’s choice to grade its other adverse events using CTCAE v4.03 is not attributed to this source. (LLM, conf=0.93)
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The primary end point of the phase 2 study was the overall response rate, which was defined as a partial response or better according to the criteria of the International Myeloma Working Group, as assessed by an independent review committee”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > METHODS > END POINTS AND ASSESSMENTS
What the sources say
- Partly supportedcites [10] sourceExperimental — accuracy not yet measured
The Response criteria section recommends IMWG criteria for clinical trials and endorses the IMWG definition of partial response; the Minimal response section also distinguishes partial response or better from minimal response. The paper does not establish that overall response rate was the primary endpoint of the particular phase 2 study or that an independent review committee assessed it (pages not provided). (LLM, conf=0.87)
- Not checked — no full text of the sourcecites [11] source
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesProbably not a substantial claim.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Of the 19 deaths due to adverse events in our study, 12 were attributed to Covid-19, which was consistent with the higher mortality observed from Covid-19 in patients with hematologic cancers during this time frame.24”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > DISCUSSION
What the sources say
- Supportedcites [24] source
The citation supports the background comparison, not the citing authors’ own count of 12 COVID-19 deaths among 19 adverse-event deaths. The Discussion reports high COVID-19 mortality in patients with hematologic malignancies and says it was substantially higher than in the general population, while cautioning that the estimate may be elevated by the large proportion of hospitalized patients. (LLM, conf=0.92)
Tests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
- Supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“median, five previous therapy lines”
- Also stated in: § PATIENTS · plain
“Patients had received a median of 5 previous lines of therapy (range, 2 to 14)”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > Abstract > RESULTS
Strength:plain· not yet calibratedn = 165Tests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
- Also stated in: § PATIENTS · plain
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Teclistamab exposure was sustained over the predetermined target level (6 μg per milliliter, based on the upper boundary of an experimentally determined range of the 90% maximal effective concentration) with a low peak-to-trough ratio (Fig. S3).”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > RESULTS > PHARMACOKINETICS, IMMUNOGENICITY, AND BIOMARKERS
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Cytokine release syndrome occurred in 119 patients (72.1%). Most events occurred after step-up and cycle 1 doses, with 6 patients (3.6%) having cytokine release syndrome in cycle 2 or later. Most events of cytokine release syndrome were grade 1 or 2 in severity and fully resolved, except for one grade 3 event”
- Also stated in: § RESULTS · plain
“cytokine release syndrome (in 72.1% of the patients; grade 3, 0.6%; no grade 4)”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > RESULTS > SAFETY
Strength:plain· not yet calibratedn = 119Tests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
- Also stated in: § RESULTS · plain
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Response rates were lower in patients with extramedullary disease, stage III disease, and at least 60% marrow replacement by plasma cells and were higher in those who had received no more than three previous lines of therapy.”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > RESULTS > EFFICACY
Strength:plain· not yet calibratedCausal:correlational· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“thrombocytopenia (in 66 [40.0%])”
- Also stated in: § RESULTS · plain
“thrombocytopenia (in 40.0%; grade 3 or 4, 21.2%)”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > RESULTS > SAFETY
Strength:plain· not yet calibratedn = 66Tests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
- Also stated in: § RESULTS · plain
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“A total of 68 patients (41.2%) died, with most deaths (41) attributed to progressive disease (Table S9). Nineteen patients died from adverse events, including 12 deaths from coronavirus disease 2019 (Covid-19). Five deaths were considered by investigators to be related to teclistamab”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > RESULTS > SAFETY
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“In addition, reductions in soluble BCMA levels occurred during the first 4 cycles of treatment in 63 of 72 evaluable patients (88%) who had a partial response or better, whereas all the evaluable patients who did not have a response (9 of 9 patients) had increased levels of soluble BCMA.”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > RESULTS > PHARMACOKINETICS, IMMUNOGENICITY, AND BIOMARKERS
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“A total of 98 patients (59.4%) received at least 6 months of teclistamab treatment, and 79 patients (47.9%) received at least 9 months of treatment.”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > RESULTS > PATIENTS
Strength:plain· not yet calibratedn = 98Tests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“All 165 patients reported having an adverse event (Table 2 and Table S5), which were grade 3 or 4 in 156 patients (94.5%).”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > RESULTS > SAFETY
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Five patients had a total of 9 events of immune effector cell–associated neurotoxicity syndrome, all either grade 1 or 2. Of these 9 events, 7 were concurrent with cytokine release syndrome, and all 9 events resolved without discontinuation or dose reduction.”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > RESULTS > SAFETY
Tests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“neutropenia (in 117 patients [70.9%])”
- Also stated in: § RESULTS · plain
“neutropenia (in 70.9%; grade 3 or 4, 64.2%)”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > RESULTS > SAFETY
Strength:plain· not yet calibratedn = 117Tests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
- Also stated in: § RESULTS · plain
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Injection-site reactions were reported in 60 patients (36.4%); all such events were grade 1 or 2.”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > RESULTS > SAFETY
Strength:plain· not yet calibratedn = 60Tests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The median time until the onset of cytokine release syndrome was 2 days (range, 1 to 6) after the most recent dose, and the median duration was 2 days (range, 1 to 9).”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > RESULTS > SAFETY
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Investigator-assessed neurotoxic events, including immune effector cell–associated neurotoxicity syndrome, were reported in 24 patients (14.5%).”
- Also stated in: § RESULTS · plain
“Neurotoxic events occurred in 24 patients (14.5%), including immune effector cell–associated neurotoxicity syndrome in 5 patients (3.0%; all grade 1 or 2).”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > RESULTS > SAFETY
Strength:plain· not yet calibratedn = 24Tests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
- Also stated in: § RESULTS · plain
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“anemia (in 86 [52.1%])”
- Also stated in: § RESULTS · plain
“anemia (in 52.1%; grade 3 or 4, 37.0%)”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > RESULTS > SAFETY
Strength:plain· not yet calibratedn = 86Tests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
- Also stated in: § RESULTS · plain
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The median time until the first response was 1.2 months (range, 0.2 to 5.5), and the median time until a best response was 3.8 months (range, 1.1 to 16.8).”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > RESULTS > EFFICACY
Strength:plain· not yet calibratedn = 165Tests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“One patient had a dose reduction during cycle 21 because of recurrent neutropenia, and 104 patients (63.0%) skipped a dose because of adverse events. Two patients discontinued teclistamab because of adverse events (grade 3 adenoviral pneumonia and grade 4 progressive multifocal leukoencephalopathy).”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > RESULTS > SAFETY
Tests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“As of March 16, 2022, 70 patients (42.4%) were continuing to receive treatment (Fig. S1), with a median treatment duration of 8.5 months (range, 0.2 to 24.4).”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > RESULTS > PATIENTS
Strength:plain· not yet calibratedn = 70Tests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Infections occurred in 126 patients (76.4%); 74 patients (44.8%) had grade 3 or 4 infections.”
- Also stated in: § RESULTS · plain
“Infections were frequent (in 76.4%; grade 3 or 4, 44.8%).”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > RESULTS > SAFETY
Strength:plain· not yet calibratedn = 126Tests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
- Also stated in: § RESULTS · plain
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The overall depth of response was highlighted by the observation that 26.7% of the patients were found to have no minimal residual disease at a sensitivity level of 10−5; these patients made up 82% of those in whom minimal residual disease could be evaluated.”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > DISCUSSION
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Cytopenias and infections were common; toxic effects that were consistent with T-cell redirection were mostly grade 1 or 2.”
- Also stated in: § DISCUSSION · plain
“Toxic effects were also common but were mainly of low grade and reversible.”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > Abstract > CONCLUSIONS
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
- Also stated in: § DISCUSSION · plain
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“The sponsor established a safety evaluation team to monitor patient safety throughout the phase 1 study. In phase 2, safety was monitored through continuous review by the sponsor.”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > METHODS > STUDY OVERSIGHT
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“In addition, subgroup analyses suggest that patients who have received no more than three previous therapy lines may have a better response rate than those who have received more than three therapies, a finding that supports the use of teclistamab in earlier therapy lines (although the confidence intervals for this finding are wide).”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > DISCUSSION
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
In the paper
“Teclistamab redirects CD3+ T cells to BCMA+ myeloma cells, resulting in T-cell activation and subsequent lysis and death of BCMA+ cells.18”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > DISCUSSION
What the sources say
- Not checked — no full text of the sourcecites [18] source
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“The study was conducted in accordance with the principles of the Declaration of Helsinki and the Good Clinical Practice guidelines of the International Council for Harmonisation.”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > METHODS > STUDY OVERSIGHT
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Toxic effects were also common but were mainly of low grade and reversible.”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > DISCUSSION
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The median relative dose intensity was high, and dose reductions and discontinuations owing to adverse events were infrequent.”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > DISCUSSION
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“The safety and efficacy populations for this analysis included all the patients who had received at least one dose of teclistamab at the recommended phase 2 dose in phase 1 or phase 2 as of September 7, 2021.”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > METHODS > STATISTICAL ANALYSIS
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesProbably not a substantial claim.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“Response rates were also compared across various prespecified subgroups, including those defined according to cytogenetic risk, refractory status, and number of previous lines of therapy.”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > METHODS > STATISTICAL ANALYSIS
Strength:plain· not yet calibratedCausal:correlational· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“For phase 2, we determined that a sample size of 100 patients would provide a power of at least 85% to establish an overall response rate of more than 30% at a one-sided significance level of 0.025, assuming an overall response rate of at least 45%.”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > METHODS > STATISTICAL ANALYSIS
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesProbably not a substantial claim.
In the paper
“Adverse events in this phase 1–2 trial were common and included low-grade cytokine release syndrome and grade 3 or 4 cytopenia and infection in a patient population that has an increased susceptibility to infection due to the immunodeficiency associated with myeloma and immunosuppressive effects of previous myeloma therapies.23”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > DISCUSSION
What the sources say
- Not checked — no full text of the sourcecites [23] source
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“Negativity for minimal residual disease was assessed by next-generation sequencing of DNA obtained from bone marrow aspirate (clonoSEQ assay, version 2.0 [Adaptive Biotechnologies]) with a threshold of 10−5 cells.”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > METHODS > END POINTS AND ASSESSMENTS
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesProbably not a substantial claim.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“The study protocol, amendments, and relevant documents were approved by the local independent ethics committee or institutional review board at each study site. All the patients provided written informed consent.”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > METHODS > STUDY OVERSIGHT
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“All the authors affirm that the trial was conducted in accordance with the study protocol and vouch for the accuracy and completeness of the data.”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > METHODS > STUDY OVERSIGHT
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
The paper relies on this without support.
Teclistamab is readily available.
“Teclistamab is readily available and has been associated with rapid onset of response after a median of approximately 1 month of treatment.”
The paper relies on this without support.
No CD3-redirecting therapy has been approved for the treatment of myeloma.
“Although clinical proof of concept has been obtained for other CD3-redirection platforms in other indications,19-21 no CD3-redirecting therapy has been approved for the treatment of myeloma.”
The paper relies on this without support.
Cross-trial comparisons are challenging to interpret owing to differences in study design and patient populations.
“Although cross-trial comparisons are challenging to interpret owing to differences in study design and patient populations, the response rates observed with teclistamab (63%) compare favorably with those of belantamab mafodotin”
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“Two BCMA-targeting bispecific antibodies, teclistamab and elranatamab, have been approved for use in patients with relapsed myeloma who have received at least 4 prior regimens.91,92”
From Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management (2024) · cites this paper as [91]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source doesn’t support the claim as written.
In the citing paper
“A number of BCMA-directed therapies, including belantamab mafodotin, idecabtagene vicleucel (ide-cel), ciltacabtagene autoleucel (cilta-cel) and teclistamab, have shown efficacy in clinical trials and are approved for the treatment of relapsed or refractory multiple myeloma4–9.”
From Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results (2023) · cites this paper as [4]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Similarly, patients with advanced disease stage (R-ISS stage III) have consistently shown poorer outcomes irrespective of the therapy received4–6,19–22.”
From Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results (2023) · cites this paper as [4]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In comparison to other BCMA-targeted T-cell-redirecting therapies, the rate of hematologic AEs with elranatamab was similar or lower after a similar follow-up4–6.”
From Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results (2023) · cites this paper as [4]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“and favorable to the BCMA-targeting antibody–drug conjugate, belantamab mafodotin (ORR 32%, median DOR 11.0 months and median PFS 2.8 months) after a median follow-up of 12.4 months4,9,19,23.”
From Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results (2023) · cites this paper as [4]
Experimental — accuracy not yet measured
The cited source says what the claim attributes to it.
In the citing paper
“Teclistamab and elranatamab are bispecific antibodies produce an immunotherapeutic effect by binding to BCMA on myeloma cells on one arm and CD3 on T cells with the other.91,92”
From Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management (2024) · cites this paper as [91]
The cited source says what the claim attributes to it.
In the citing paper
“The primary endpoint in phase 2 was overall response rate per IMWG criteria,11 based on independent committee review, which was defined as the proportion of patients who had a partial response or better.”
From Safety and activity of talquetamab in patients with relapsed or refractory multiple myeloma (MonumenTAL-1): a multicentre, open-label, phase 1-2 study. (2025) · cites this paper as [11]
The cited source says what the claim attributes to it.
In the citing paper
“Teclistamab, a bispecific antibody targeting CD3×BCMA,6 demonstrated deep and durable responses in heavily pretreated RRMM in the phase 1/2 MajesTEC-1 study.7,8”
From Teclistamab plus Daratumumab in Relapsed or Refractory Multiple Myeloma (2026) · cites this paper as [8]
The cited source says what the claim attributes to it.
In the citing paper
“Cytokine release syndrome incidence was lower than that observed with teclistamab monotherapy in MajesTEC-1 (60.1% vs. 72.1%, respectively),8 with most events being grade 1 and occurring during the step-up dosing schedule.”
From Teclistamab plus Daratumumab in Relapsed or Refractory Multiple Myeloma (2026) · cites this paper as [8]
The cited source says what the claim attributes to it.
In the citing paper
“In this trial, 165 RRMM patients were treated with Teclistamab, and the following key outcomes were observed 63.0% ORR, 58.8% VGPR, and 39.4% CR. These results demonstrate the significant clinical activity of Teclistamab in RRMM patients who have received multiple prior lines of therapy. The high ORR, VGPR rate, and CR rate indicate substantial anti-myeloma activity of Teclistamab. Additionally, t”
From Multiple myeloma: signaling pathways and targeted therapy (2024) · cites this paper as [209]
The cited source says what the claim attributes to it.
In the citing paper
“The lower response rate observed in patients with extramedullary disease reflects the historically poor prognosis in this subgroup and has also been observed with other anti-BCMA-targeted agents such as belantamab mafodotin and teclistamab4,19.”
From Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results (2023) · cites this paper as [4]
Citations
Cites
Lee, D. W., Santomasso, B. D., Locke, F. L., Ghobadi, A., Turtle, C. J., Brudno, J. N., Maus, M. V., Park, J. H., Mead, E., Pavletic, S., et al. (2019) · Biology of Blood and Marrow Transplantation · doi:10.1016/j.bbmt.2018.12.758 · Cited by 3,675
Kumar, S., Paiva, B., Anderson, K. C., Durie, B., Landgren, O., Moreau, P., Munshi, N., Lonial, S., Bladé, J., Mateos, M.-V., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30206-6 · Cited by 3,061
Self-citationIdecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma.
Munshi, N. C., Anderson, L. D., Shah, N., Madduri, D., Berdeja, J., Lonial, S., Raje, N., Lin, Y., Siegel, D., Oriol, A., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2024850 · Cited by 2,560
Self-citationBerdeja, J. G., Madduri, D., Usmani, S. Z., Jakubowiak, A., Agha, M., Cohen, A. D., Stewart, A. K., Hari, P., Htut, M., Lesokhin, A., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00933-8 · Cited by 1,756
Self-citationRajkumar, S. V., Harousseau, J.-L., Durie, B., Anderson, K. C., Dimopoulos, M., Kyle, R., Blade, J., Richardson, P., Orlowski, R., Siegel, D., et al. (2011) · Blood · doi:10.1182/blood-2010-10-299487 · Cited by 1,036
Self-citationMultiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†
Dimopoulos, M. A., Moreau, P., Terpos, E., Mateos, M. V., Zweegman, S., Cook, G., Delforge, M., Hájek, R., Schjesvold, F., Cavo, M., et al. (2021) · Annals of Oncology · doi:10.1016/j.annonc.2020.11.014 · Cited by 900
Self-citationLonial, S., Lee, H. C., Badros, A., Trudel, S., Nooka, A. K., Chari, A., Abdallah, A.-O., Callander, N., Lendvai, N., Sborov, D., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30788-0 · Cited by 812
Self-citationVijenthira, A., Gong, I. Y., Fox, T. A., Booth, S., Cook, G., Fattizzo, B., Martín-Moro, F., Razanamahery, J., Riches, J. C., Zwicker, J., et al. (2020) · Blood · doi:10.1182/blood.2020008824 · Cited by 625
Shah, N., Chari, A., Scott, E., Mezzi, K., & Usmani, S. Z. (2020) · Leukemia · doi:10.1038/s41375-020-0734-z · Cited by 490
Self-citationBispecific T‐cell engagers for cancer immunotherapy
Huehls, A. M., Coupet, T. A., & Sentman, C. L. (2014) · Immunology and Cell Biology · doi:10.1038/icb.2014.93 · Cited by 478
Flagged first, then by citations
Cited by
Sorted by citations
Items 301–400 of 1,251
Liao, X., Qi, T., Zhou, J., Liu, C., & Cao, Y. (2024) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.3302 · Cited by 15
“34 The long-term dose of teclistamab for the treatment of MM is 1.5 mg/kg every week by subcutaneous injection.”
InfluentialKfir-Erenfeld, S., Asherie, N., Lebel, E., Vainstein, V., Assayag, M., Sharon, T. D., Grisariu, S., Avni, B., Elias, S., Alexander-Shani, R., et al. (2024) · Blood Advances · doi:10.1182/bloodadvances.2024012967 · Cited by 12
“…lines and the presence of HR cytogenetic and EMD and a trend toward a more differentiated status of CAR + T cells in the FP. Patients with these RFs had suboptimal responses to HBI0101 but may also have dismal outcomes with other strategies 27-29 and hence represent a signi fi cant unmet need.”
Shastri, P. N., Shah, N., Lechmann, M., Mody, H. R., Retter, M. W., Zhu, M., Li, T. R., Wang, J., Shaik, M. N., Zheng, X., et al. (2024) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.3439 · Cited by 15
Antibody–Drug Conjugates for Multiple Myeloma: Just the Beginning, or the Beginning of the End?
Ray, U., & Orlowski, R. Z. (2023) · Pharmaceuticals · doi:10.3390/ph16040590 · Cited by 17
“Of further concern is the competition provided by two commercially available CAR T-cells targeting BCMA, including idecabtagene vicleucel [98] and ciltacabtagene autoleucel [99], and the BCMA bispecific teclistamab [100].”
BackgroundT cell-dependent bispecific therapy enhances innate immune activation and antibody-mediated killing
Besla, R., Penuel, E., Del Rosario, G., Cosino, E., Myrta, S., Dillon, M., Lazar, G. A., Nickles, D., Spiess, C., Yu, S.-F., et al. (2024) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-23-0072 · Cited by 13
Bispecific antibody targets and therapies in multiple myeloma
Rees, M. J., Abdallah, N., Yohannan, B., & Gonsalves, W. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1424925 · Cited by 16
Verma, V., & Sharma, G. (2024) · Clinical and Experimental Medicine · doi:10.1007/s10238-024-01520-y · Cited by 15
“Although cross-trial comparison is not ideal, available evidence indicates toward similar efficacy and better tolerability of BiTEs compared to CAR-T cell therapy [4, 9, 17, 18].”
Ravi, G., Richard, S., Kumar, S. K., Atrash, S., Liedtke, M., Kaur, G., Derman, B. A., Bergsagel, P. L., Mailankody, S., McCarthy, P., et al. (2025) · Leukemia · doi:10.1038/s41375-025-02518-5 · Cited by 15
T-Cell Engager Therapy in Prostate Cancer: Molecular Insights into a New Frontier in Immunotherapy
Kwon, W., & Joung, J. Y. (2025) · Cancers · doi:10.3390/cancers17111820 · Cited by 15
“Trials of agents such as blinatumomab [31], glofita-mab [32], and teclistamab [33] have demonstrated that response rates can exceed those of traditional chemotherapy in refractory settings, even producing durable remission in some patients.”
Schreiber, S., Al‐Dubai, M., Vielhaber, S., et al. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.06.029 · Cited by 13
Bakogeorgou, S., Filippatos, C., Malandrakis, P., Tentolouris, A., Terpos, E., Gavriatopoulou, M., & Ntanasis‐Stathopoulos, I. (2025) · Cancers · doi:10.3390/cancers17172727 · Cited by 13
“After further screening, six records involving 850 RRMM patients from clinical trials on BsAbs met the full eligibility criteria and were included in this analysis [27–32].”
Timing Genomic Antigen Loss in Multiple Myeloma Treated with T Cell–Redirecting Immunotherapies
Papadimitriou, M., Ahn, S., Diamond, B. T., Lee, H., McIntyre, J. B., Truger, M. S., Durante, M. A., Ziccheddu, B., Osz, K., Landgren, O., et al. (2025) · Blood Cancer Discovery · doi:10.1158/2643-3230.bcd-25-0005 · Cited by 23
Self-citationNew Strategies for the Treatment of Older Myeloma Patients
Larocca, A., Cani, L., Bertuglia, G., Bruno, B., & Bringhen, S. (2023) · Cancers · doi:10.3390/cancers15102693 · Cited by 14
“Nonetheless, only 15% of patients included in the study were aged ≥75 years [87].”
BackgroundMartínez‐López, J., Bailey, A., Lambert, A., Luke, E., Ribbands, A., Erler-Yates, N., Valluri, S., Haefliger, B., & Gay, F. (2023) · Future Oncology · doi:10.2217/fon-2023-0021 · Cited by 16
“These include, but are not limited to, the DREAMM-2 [36 , 37] , STORM [38 , 39] , HORIZON [40] , KarMMa [41] , CARTITUDE-1 [42] , MajesTEC-1 studies [43] and Talquetamab studies [43] .”
Self-citationMonoclonal Antibodies in the Treatment of Multiple Myeloma
van de Donk, N. W. C. J., & Zweegman, S. (2023) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2023.12.002 · Cited by 16
Self-citationUttervall, K., Tӓtting, L., Lemonakis, K., et al. (2024) · Cancer Medicine · doi:10.1002/cam4.7048 · Cited by 13
Self-citationBarbieri, E., Martino, E. A., Rivolti, E., Quaresima, M., Vigna, E., Neri, A., Morabito, F., & Gentile, M. (2024) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2024.2357382 · Cited by 13
“The efficacy and the safety of teclistamab and elranatamab were demonstrated in the registered trials MajesTEC-1 [109] and MagnetisMM-1 [110], respectively, wherein ORR reached 60% and median PFS was 11 months.”
BackgroundImproving outcomes with anti-BCMA bispecific antibodies with attention to infection
Yee, A. J. (2024) · Blood Cancer Journal · doi:10.1038/s41408-024-01091-x · Cited by 17
“%) and elranatamab (69.9%; 39.8%; 6.5%), respectively [1 – 3].”
InfluentialCurrent landscape of CD3 bispecific antibodies in hematologic malignancies
Kassner, J. D., Abdellatif, B., Yamshon, S., Monge, J., & Kaner, J. D. (2024) · Trends in cancer · doi:10.1016/j.trecan.2024.06.001 · Cited by 15
Tyrna, P., Procyk, G., Szeleszczuk, Ł., & Młynarczuk-Biały, I. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25168949 · Cited by 15
“Clinical trials of agents reviewed in this article are listed in Table 2. cytokine release syndrome, cytopenias, infections, neurotoxicity [136] BTZ—bortezomib, CFZ—carfilzomib, CI—95% confidence interval, DXM—dexamethasone, HR—hazard ratio, MM—multiple myeloma, mos.”
BackgroundUpdates on Therapeutic Strategies in the Treatment of Relapsed/Refractory Multiple Myeloma
Parekh, D. S., Tiger, Y. K., Jamouss, K. T., Hassani, J., Zerdan, M. B., & Raza, S. (2024) · Cancers · doi:10.3390/cancers16172931 · Cited by 16
“Neutropenia, anemia, thrombocytopenia, and infection were also commonly reported [17].”
BackgroundUrushihara, R., Takezako, N., Yoroidaka, T., Yamashita, T., Murata, R., Satou, K., Nakao, S., & Takamatsu, H. (2023) · eJHaem · doi:10.1002/jha2.633 · Cited by 12
“Because MRD levels can be greatly reduced by the development of novel agents such as proteasome inhibitors, IMiDs, monoclonal antibodies [17], BiTEs [18], and CAR-T [19, 20], innovative high-sensitivity MRD detection methods have become increasingly important.”
BackgroundTargeting B Cell Maturation Antigen in Patients with Multiple Myeloma: Current Perspectives
Shrivastava, T., van Rhee, F., & Hadidi, S. A. (2023) · OncoTargets and Therapy · doi:10.2147/ott.s370880 · Cited by 13
“1% of patients, and thrombocytopenia in 40% of patients.(47) Based on these results, teclistamab appears to be a promising agent awaiting long-term outcomes and the results of future randomized clinical trials.”
BackgroundInfluentialPan, D., & Richter, J. R. (2023) · Cancer Management and Research · doi:10.2147/cmar.s372237 · Cited by 15
“5 mg/kg.(3) Patients received an initial step-up dose of 0.”
BackgroundMethodInfluentialArvanitis, P., Farmakiotis, D., & Pelcovits, A. (2024) · Current Oncology · doi:10.3390/curroncol31050202 · Cited by 13
Comprehensive analysis of adverse events associated with T-cell engagers using the FAERS database
Le, X., Zhang, Y., & Ma, J. (2025) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2025.2470875 · Cited by 14
Davis, J. A., Snyder, J. A., Rice, M. L., Moore, D. C., Cahoon, C. R., Julian, K. L., Wagner, C. B., Granger, K., Green, K. M., Atrash, S., et al. (2025) · Blood Cancer Journal · doi:10.1038/s41408-025-01222-y · Cited by 16
Dima, D., Afrough, A., Goel, U., et al. (2025) · Blood Advances · doi:10.1182/bloodadvances.2025016059 · Cited by 12
Self-citationJain, M. D., Abramson, J. S., & Ansell, S. M. (2025) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk-25-473916 · Cited by 11
A roadmap to implementing outpatient administration of bispecific antibodies in multiple myeloma
Garfall, A. L., Banerjee, R. K., Frenzel, L., Khandanpour, C., Lin, Y., Ottoni, E. L., Rifkin, R. M., Rockwell, S., Rodriguez, C., Villefort, H., et al. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1630146 · Cited by 21
Self-citationTechaapornkun, P., Rojpalakorn, W., Mejun, N., Khaniya, A., Thammahong, A., Thu, M. S., Hirankarn, N., & Pitakkitnukun, P. (2025) · Annals of Hematology · doi:10.1007/s00277-025-06524-6 · Cited by 14
Multimodal antigenic escape to GPRC5D-targeted T cell engagers in multiple myeloma
Lee, H., Ahn, S., Gonzales, G. A., Leblay, N., Barakat, E., Greening, D., Colarusso, P., Canton, J., Benaoudia, S., Hasheminasabgorji, E., et al. (2026) · Nature Medicine · doi:10.1038/s41591-025-04175-8 · Cited by 18
“Although these agents induce deep remissions in patients with relapsed refractory MM, resistance invariably develops in most patients 1–11 .”
Self-citationProgressive multifocal leukoencephalopathy in multiple myeloma
Hoeynck, B., Cohen, A. D., Stadtmauer, E. A., et al. (2022) · European Journal Of Haematology · doi:10.1111/ejh.13909 · Cited by 12
“This case was previously reported with the results of the clinical trial on which he was enrolled.(26)”
BackgroundResultSelf-citationMarcinek, A., Brauchle, B., Rohrbacher, L., Hänel, G., Philipp, N., Märkl, F., Strzalkowski, T., Lacher, S. M., Udiljak, D., Spiekermann, K., et al. (2023) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-023-03439-x · Cited by 13
Aleman, A., van Kesteren, M., Zajdman, A. K., Srivastava, K., Cognigni, C., Mischka, J., Chen, L., Upadhyaya, B., Serebryakova, K., Nardulli, J., et al. (2023) · EBioMedicine · doi:10.1016/j.ebiom.2023.104886 · Cited by 10
“27,28 Immune composition has been reported to being altered with NK cell fratricide in anti-CD38 therapy and B cell reduction in anti-BCMA therapy.”
BackgroundSelf-citationVisram, A., Torre, A. H. D. L., White, D., Su, J., Masih-Khan, E., Chu, M., Jimenez-Zepeda, V., Mccurdy, A., LeBlanc, R., Song, K., et al. (2023) · Blood Cancer Journal · doi:10.1038/s41408-023-00946-z · Cited by 10
Pasvolsky, O., Ghanem, S., Milton, D. R., et al. (2024) · Blood Cancer Journal · doi:10.1038/s41408-023-00973-w · Cited by 12
Next-Generation Therapies for Multiple Myeloma
Meermeier, E. W., Bergsagel, P. L., & Chesi, M. (2024) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-061421-014236 · Cited by 12
Hamadeh, I. S., Shekarkhand, T., Rueda, C., Firestone, R., Wang, A. X., Korde, N., Hultcrantz, M. L., Lesokhin, A. M., Mailankody, S., Hassoun, H., et al. (2024) · Blood Advances · doi:10.1182/bloodadvances.2024012724 · Cited by 13
Self-citationPuertas, B., Fernández-Sánchez, A., Alejo, E., Rey-Búa, B., Martín‐López, A. Á., López, E. P., López-Parra, M., López‐Corral, L., Gutierrez, N. C., García‐Sánz, R., et al. (2024) · Blood Advances · doi:10.1182/bloodadvances.2024012773 · Cited by 12
“5,6 10-16 However, no studies have compared the outcomes with both therapies.”
Self-citationRoussel, M., Texier, N., Naël, V., Bitetti, J., Paka, P., Kerbouche, N., Sail, L., Colin, X., & Leleu, X. P. (2024) · European Journal Of Haematology · doi:10.1111/ejh.14222 · Cited by 13
Beyond BCMA: newer immune targets in myeloma
Tan, M. S. Y., Chen, Y.-X., & Smith, E. L. (2024) · Blood Advances · doi:10.1182/bloodadvances.2023010856 · Cited by 12
Bispecific Antibodies for the Management of Relapsed/Refractory Multiple Myeloma
Tacchetti, P., Barbato, S., Mancuso, K., Zamagni, E., & Cavo, M. (2024) · Cancers · doi:10.3390/cancers16132337 · Cited by 16
“[7,33].”
BackgroundMethodInfluentialLu, K., Wang, W., Liu, Y., Xie, C., Liu, J., & Xing, L. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1413494 · Cited by 13
Tarlatamab-dlle: A New Hope for Patients with Extensive-Stage Small-Cell Lung Cancer
Goyal, P. K., & Sangwan, K. (2024) · Current Treatment Options in Oncology · doi:10.1007/s11864-024-01268-3 · Cited by 12
Cai, Z., Xia, Z., He, A., Dong, Y., Wang, Y., Liao, A., Song, Y., Song, J., Uhlar, C., Chastain, K. M., et al. (2024) · Cancer · doi:10.1002/cncr.35665 · Cited by 12
Self-citationMechanisms for resistance to BCMA-targeted immunotherapies in multiple myeloma
Yue, T., Sun, Y., Dai, Y., & Jin, F. (2025) · Blood Reviews · doi:10.1016/j.blre.2025.101256 · Cited by 15
Wattana, M. K., Rowland, J., Qdaisat, A. Z., Levavi, H., Anagnostou, T., Sanchez, L. J., Friedlander, P. A., Rohs, N. C., Lipe, D. N., & Richter, J. R. (2025) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2025.102889 · Cited by 14
Chunara, F., Lugo, C., Osinski, K. I., Shah, M. R., Shah, N. N., Kent, J., Mohyuddin, G. R., Radhakrishnan, S. V., Kaur, G., Chakraborty, R., et al. (2025) · Blood Cancer Journal · doi:10.1038/s41408-025-01254-4 · Cited by 12
“The bispeci fi c antibodies (bsAbs) teclistamab and talquetamab have received United States Food and Drug Administration (FDA) approval for use in relapsed/refractory multiple myeloma (MM) following remarkable single-agent activity in early-phase clinical trials [1 – 3].”
Recent development in bispecific antibody immunotherapy for hematological malignancies
Han, L., Wang, X., Jiang, Z., Guo, X., & Yu, J. (2025) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2025.104752 · Cited by 12
Mungalov, R. V., Mushenkova, N. V., Chudakov, D. M., & Turchaninova, M. A. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1551424 · Cited by 12
Off-the-shelf CAR T cells for multiple myeloma
Brudno, J. N., & Kochenderfer, J. N. (2023) · Nature Medicine · doi:10.1038/s41591-022-02195-2 · Cited by 12
Granger, K., Gaffney, K. J., & Davis, J. A. (2023) · Journal of Oncology Pharmacy Practice · doi:10.1177/10781552231154809 · Cited by 14
“Accelerated approval for teclistamab was based upon the results of the MajesTEC-1 study.(11,12) MajesTEC-1 was a phase 1/2, open-label, single-arm, multi-center study that included adults with R/R multiple myeloma and progressive disease.”
MethodPharmacological Profile of Novel Anti-cancer Drugs Approved by USFDA in 2022: A Review
Sangwan, K., Sharma, V., & Goyal, P. K. (2023) · Current Molecular Medicine · doi:10.2174/1566524023666230622151034 · Cited by 12
Proteomic prediction of common and rare diseasesPreprint
Carrasco-Zanini, J., Pietzner, M., Davitte, J., Surendran, P., Croteau-Chonka, D., Robins, C., Torralbo, A., Tomlinson, C., Fitzpatrick, N., Ytsma, C., et al. (2023) · medRxiv · doi:10.1101/2023.07.18.23292811 · Cited by 14
Ishida, T., Kuroda, Y., Matsue, K., Komeno, T., Ishiguro, T., Ishikawa, J., Ito, T., Kosugi, H., Sunami, K., Nishikawa, K., et al. (2024) · International Journal of Hematology · doi:10.1007/s12185-024-03884-z · Cited by 13
“The study has 2 parts: (1) phase 1: the dose-escalation study, to assess the safety and tolerability of the RP2D of teclistamab identified in the first-in-human global MajesTEC-1 study [12, 18]; (2) phase 2: to evaluate the efficacy and safety of the RP2D in Japanese patients with RRMM.”
InfluentialBesliu, C., Tănase, A., Rotaru, I., Espinoza, J., Vidal, L., Poelman, M., Juan, M., de Larrea, C. F., & Saini, K. S. (2025) · Cancers · doi:10.3390/cancers17030525 · Cited by 15
“…disease, the ≥ CR rate was 73.1% with CAR T cell therapy ciltacabtagene autoleucel (Cilta-cel) in the CARTITUDE-4 trial [28] and 39.4% in patients with RRMM and multiple prior lines of therapy treated with the T cell engager bispecific antibody teclistamab in the MajesTEC-1 trial [29].”
InfluentialA trispecific antibody engaging T cells with tumour and myeloid cells augments antitumour immunity
Yang, C., Guo, S., Ye, K., Ding, Y., Zhao, X., Yang, Y., Sun, B., Qian, S., Cai, M., Liu, L., et al. (2025) · Nature Biomedical Engineering · doi:10.1038/s41551-025-01569-4 · Cited by 15
Administration of teclistamab in four patients with multiple myeloma requiring hemodialysis
Khouderchah, C. J., Ochs, M. A., Pianko, M. J., et al. (2024) · Journal of Oncology Pharmacy Practice · doi:10.1177/10781552241242022 · Cited by 11
Li, J., Clark, R., Slaga, D., et al. (2024) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-23-0910 · Cited by 11
T-cell exhaustion in multiple myeloma
Żyłka, K., Kubicki, T., Gil, L., & Dytfeld, D. (2024) · Expert Review of Hematology · doi:10.1080/17474086.2024.2370552 · Cited by 15
“They effectively lead to deep remissions in patients with refractory and/or relapsed (R/R) disease [5–10].”
BackgroundDimopoulos, M. A., Migkou, M., Bhutani, M., Ailawadhi, S., Kalff, A., Walcott, F. L., Pore, N., Brown, M., Wang, F., Cheng, L., et al. (2024) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2024.2373331 · Cited by 14
“BCMA-directed BITE therapies have also demonstrated efficacy, with some studies reporting response rates >60% and durable responses in patients with triple class-exposed R/R MM [9].”
Li, C. L., Yuan, X. Y., & Yi, P. (2024) · Cell Biochemistry and Function · doi:10.1002/cbf.70011 · Cited by 15
Zabaleta, A., Puig, N., Cedena, M., Oliver‐Caldés, A., Pérez, J. J., Moreno, C., Tamariz‐Amador, L., Rodríguez‐Otero, P., Prósper, F., González‐Calle, V., et al. (2024) · American Journal of Hematology · doi:10.1002/ajh.27526 · Cited by 11
“Of note, there were small increments in MRD negative rates at months 3 and 6 after treatment initiation because in some patients the BM aspirate at month 1 was severely hemodiluted and these patients were considered as MRD positive in the ITT analyses.”
Self-citationAntibody-Based Immunotherapies for the Treatment of Hematologic Malignancies
Jureczek, J., Kałwak, K., & Dzięgiel, P. (2024) · Cancers · doi:10.3390/cancers16244181 · Cited by 12
“The ORR achieved 65%, with a median PFS of 11.3 months [94].”
InfluentialMultiple Myeloma: Improved Outcomes Resulting from a Rapidly Expanding Number of Therapeutic Options
Mettias, S., ElSayed, A., Moore, J., & Berenson, J. R. (2025) · Targeted Oncology · doi:10.1007/s11523-024-01122-4 · Cited by 12
Pasvolsky, O., Dima, D., Feng, L., et al. (2025) · Blood Cancer Journal · doi:10.1038/s41408-025-01297-7 · Cited by 11
Self-citationDuffy, A. M., Goenka, A., Azeem, M. I., et al. (2025) · Journal of Clinical Investigation · doi:10.1172/jci192927 · Cited by 11
Self-citationMann, H., & Comenzo, R. L. (2022) · OncoTargets and Therapy · doi:10.2147/ott.s305429 · Cited by 15
Outcomes of patients with light chain ( AL ) amyloidosis after failure of daratumumab‐based therapy
Theodorakakou, F., Fotiou, D., Spiliopoulou, V., Ρούσσου, Μ., Malandrakis, P., Ntanasis‐Stathopoulos, I., Migkou, M., Eleutherakis‐Papaiakovou, E., Kanellias, N., Papanikolaou, A., et al. (2023) · British Journal of Haematology · doi:10.1111/bjh.19042 · Cited by 12
Engineering de novo binder CAR-T cell therapies with generative AIPreprint
Mergen, M., Abele, D., Koleci, N., Fernandez, A. S., Sugden, M., Holzleitner, N., Carr, A., Rieger, L., Leone, V., Reichert, M., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.11.25.625151 · Cited by 12
Gordan, L., Bensimon, A. G., Mu, F., Kim, N., Wu, B., Lin, D., Paner, A., Fowler, J., Marshall, A., Sanden, S. V., et al. (2025) · Journal of Medical Economics · doi:10.1080/13696998.2025.2514909 · Cited by 10
“The ORR in each trial (as of the latest data readout 18,19 ) had not changed since an earlier readout 20,21 , implying that no additional patients had achieved response in the intervening months of follow-up.”
van de Donk, N. W. C. J., Chari, A., Martin, T. G., Krishnan, A. Y., Rasche, L., Ye, J. C., Popat, R., Lipe, B. C., Rodriguez, C., Schinke, C., et al. (2025) · Cancer Medicine · doi:10.1002/cam4.71276 · Cited by 10
Self-citationFleischer, A., Roll, M., Frenking, J. H., Panther, F., Gelbrich, G., Strunz, P., Riedhammer, C., Peter, J., Mersi, J., Waldschmidt, J. M., et al. (2025) · Cancer Medicine · doi:10.1002/cam4.71401 · Cited by 10
Bar, N., Martin, T., Hofmeister, C. C., Mateos, M., Hansson, M., Paris, L., Namburi, S., Ribas, P., Santoro, A., Rodríguez-Otero, P., et al. (2026) · Leukemia · doi:10.1038/s41375-025-02841-x · Cited by 12
“[7, 8, 20].”
Self-citationvan de Donk, N. W. C. J., Sonneveld, P., & Einsele, H. (2026) · Blood · doi:10.1182/blood.2025032536 · Cited by 13
Self-citationMolecularly Targeted Therapies in Oncology: Mechanisms, Resistance, and Combination Strategies
Giercuszkiewicz-Haśnik, K., MORAK-MŁODAWSKA, B. I., & Jeleń, M. (2026) · Molecules · doi:10.3390/molecules31071195 · Cited by 14
Outcomes of Penta-Refractory Multiple Myeloma Patients Treated with or without BCMA-Directed Therapy
Atrash, S., Mammadzadeh, A., Peng, F., Alkharabsheh, O. A., Afrough, A., Cui, W., Mahmoudjafari, Z., Abdallah, A.-O. A., & Hashmi, H. (2023) · Cancers · doi:10.3390/cancers15112891 · Cited by 9
“Despite the similarity between triple-class refractory and penta-refractory myeloma, the latter conveys extra concerns about T-cell fitness due to multiple previous LOTs.”
BackgroundInfluentialInnovative drugs promote precision cancer therapy
Huang, X., Zhu, M., Chen, R., Ni, J., Zhao, W., Li, S., Lü, X., Jiao, H., & Cao, X. (2023) · Clinical Cancer Bulletin · doi:10.1007/s44272-023-00002-8 · Cited by 12
Mo, C. C., Richardson, E., Calabretta, E., Corrado, F., Kocoglu, M. H., Baron, R. M., Connors, J. M., Iacobelli, M., Wei, L. J., Rapoport, A. P., et al. (2024) · Blood Reviews · doi:10.1016/j.blre.2024.101218 · Cited by 10
Graf, K. C., Davis, J. A., Cendagorta, A. M., Granger, K., Gaffney, K. J., Green, K., Hess, B. T., & Hashmi, H. (2024) · eJHaem · doi:10.1002/jha2.906 · Cited by 10
“In October 2022, teclistamab was the first bispecific agent to receive US Food and Drug Administration (USFDA) approval for RRMM based on the phase I/II MajesTEC-1study[4].”
BackgroundResultInfluentialRafei, H., & Rezvani, K. (2024) · British Journal of Haematology · doi:10.1111/bjh.19668 · Cited by 10
Emerging Immune Checkpoint Inhibitors for the Treatment of Oropharyngeal Squamous Cell Carcinoma
Ravi, P., & Babu, S. (2024) · Oral Oncology Reports · doi:10.1016/j.oor.2024.100650 · Cited by 9
Zabaleta, A., Blanco, L., Kim, P. S., Bisht, K. K., Wang, H., de Velde, H. J. V., Lasa, M., Tamariz‐Amador, L., Rodríguez‐Otero, P., Miguel, J. F. S., et al. (2024) · British Journal of Haematology · doi:10.1111/bjh.19784 · Cited by 11
Self-citationImmunotargets and Therapy for Systemic Lupus Erythematosus
Mok, C. C. (2025) · ImmunoTargets and Therapy · doi:10.2147/itt.s485650 · Cited by 11
Venous Thromboembolic Events in Cancer Immunotherapy: A Narrative Review
Fowler, C., & Pastores, S. M. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14144926 · Cited by 12
Bispecific Antibodies in Hematologic Malignancies: Attacking the Frontline
Shastri, T., Trabolsi, A., Arumov, A., & Schatz, J. H. (2025) · BioDrugs · doi:10.1007/s40259-025-00735-z · Cited by 12
“Patients with prior exposure to a proteasome inhibitor, immunomodulatory agent, and anti-CD38 antibody, for teclistamab treat-ment, were found to have an ORR of 63% with the use of teclistamab in the MajesTEC-1 study [67].”
InfluentialMeermeier, E. W., Pfeffer, K., Stein, C. K., Sharik, M. E., Du, M. T., Alvarado, Y. T., Shi, C., Zhu, Y. X., Bergsagel, P. L., & Chesi, M. (2025) · Blood · doi:10.1182/blood.2025029215 · Cited by 14
Characterization of anti-CD3 antibodies in clinically available bispecific T cell engagers
Lee, H., Lee, Y., & Chung, J. (2025) · Seminars in Hematology · doi:10.1053/j.seminhematol.2025.08.004 · Cited by 10
Pasvolsky, O., Gaballa, M., Milton, D. R., Masood, A., Sami, S. S., Tanner, M. R., Bashir, Q., Srour, S. A., Saini, N. Y., Ramdial, J., et al. (2023) · Transplantation and Cellular Therapy · doi:10.1016/j.jtct.2023.01.010 · Cited by 10
Fang, J., & Zhou, F. (2023) · Annals of Hematology · doi:10.1007/s00277-023-05444-7 · Cited by 12
Verbruggen, S. W., Freeman, C. L. L., & Freeman, F. E. (2024) · Cancers · doi:10.3390/cancers16050889 · Cited by 11
“More recently, T-cell engaging (TCE) therapies have also been approved and are available in a similar population of patients with RRMM after exposure to greater than or equal to four prior lines of therapy [17–19].”
BackgroundFirst report of teclistamab in a patient with relapsed AL amyloidosis and multiple myeloma
Leung, N., Chapman, J. A., & Bhatia, S. (2023) · eJHaem · doi:10.1002/jha2.772 · Cited by 10
“Teclistamab is the first BCMA targeting bispecific T-cell engager approved for treatment of relapsed or refractory MM [12].”
BackgroundAbdelmotaleb, O., Schneider, A., Waldhauer, I., Sam, J., Höfer, T., Lechmann, M., Freimoser–Grundschober, A., Giusti, A. M., Essig, K., Nikić, T., et al. (2025) · mAbs · doi:10.1080/19420862.2025.2584374 · Cited by 11
Treatment of Multiple Myeloma: ASCO–Ontario Health (Cancer Care Ontario) Living Guideline
Hicks, L. K., Messersmith, H. J., Hadidi, S. S. A. A., Banerjee, R. K., Derman, B. A., Kumar, S. K., Wildes, T. M., Bal, S., Bhella, S., Chmielewski, C., et al. (2026) · Journal of Clinical Oncology · doi:10.1200/jco-25-02587 · Cited by 11
Self-citationPasvolsky, O., Pasyar, S., Bassett, R. L., Khan, H., Tanner, M. R., Bashir, Q., Srour, S. A., Saini, N. Y., Lin, P. Y., Ramdial, J., et al. (2023) · Cancer · doi:10.1002/cncr.35171 · Cited by 9
“The anti ‐ myeloma armamentarium is constantly evolving, and new modalities, such as B ‐ cell maturation antigen ‐ directed CAR T 19 and bispecific antibodies, 20 have shown efficacy in inducing deep responses in patients with relapsed/refractory MM.”
BackgroundCilta-cel, a BCMA-targeting CAR-T therapy for patients with multiple myeloma
Jagannath, S., Jackson, C. C., Schecter, J. M., Lendvai, N. K., Sun, H., Akram, M., Patel, N., & Martin, T. G. (2024) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2024.2352591 · Cited by 13
Self-citationMorè, S., Corvatta, L., Manieri, V. M., Morsia, E., & Offidani, M. (2024) · Cancers · doi:10.3390/cancers16122263 · Cited by 9
“In the setting of bispecific antibodies, the all grades CRS rate is about 50–70%, with grade ≥ 3 CRS lower than 5% (teclistamab 72%/0.6%, elranatamab 57%/0, REGN5458 50%/0.6%, alnuctamab 53%/0, ABBV-383 70%/ 5%), with differences based on dosing [85–89].”
BackgroundInfluentialGonugunta, A. S., Mohlere, V., & Abid, M. B. (2024) · British Journal of Haematology · doi:10.1111/bjh.19633 · Cited by 10
Zhang, Y., Shan, C., Zhang, X., Liu, Y., Xia, Y., & Wang, Y. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1400101 · Cited by 9
Metadata
- Authors
- Moreau, P., Garfall, A. L., van de Donk, N. W. C. J., Nahi, H., San-Miguel, J. F., Oriol, A., Nooka, A. K., Martin, T., Rosinol, L., Chari, A., Karlin, L., Benboubker, L., Mateos, M.-V., Bahlis, N., Popat, R., Besemer, B., Martínez-López, J., Sidana, S., Delforge, M., Pei, L., Trancucci, D., Verona, R., Girgis, S., Lin, S. X. W., Olyslager, Y., Jaffe, M., Uhlar, C., Stephenson, T., Van Rampelbergh, R., Banerjee, A., Goldberg, J. D., Kobos, R., Krishnan, A., & Usmani, S. Z.
- Affiliations
- Karolinska University Hospital (SE)
- From the Hematology Clinic, University Hospital Hôtel-Dieu, Nantes (P.M.), Service d’Hématologie Clinique, Centre Hospitalier Lyon Sud, Pierre-Bénite (L.K.), and Service d’Hématologie et Thérapie Cellulaire, Hôpital Bretonneau, Centre Hospitalier Régional Universitaire, Tours (L.B.) — all in France; Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia (A.L.G.), and Janssen Research and Development, Spring House (R.V., S.G., S.X.W.L., C.U., T.S., A.B.) — both in Pennsylvania; the Department of Hematology, Amsterdam University Medical Center, Vrije Universiteit Amsterdam, Cancer Center Amsterdam, Amsterdam (N.W.C.J.D.); Karolinska University Hospital at Huddinge, Stockholm (H.N.); Clínica Universidad de Navarra, Centro de Investigación Médica Aplicada, Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Instituto de Investigación Sanitaria de Navarra, Pamplona (J.F.S.-M.), Institut Català d’Oncologia and Institut Josep Carreras, Hospital Germans Trias i Puj...
- City Of Hope National Medical Center (US)
- Memorial Sloan Kettering Cancer Center (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2022-08-11
- Volume
- 387
- Issue
- 6
- Pages
- 495-505
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC10587778
- OpenAlex
- W4282033105
- Cited by
- 1,269
- References
- 25
- Citations by year
- 2026: 335 · 2025: 341 · 2024: 320 · 2023: 231 · 2022: 39
- FWCI
- 169.47
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Amsterdam UMC (VU Amsterdam) - Institutional Repository (publishedVersion)
- PubMed Central (acceptedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Lirias (submittedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- Funders
- Janssen Research & Development, LLC
- Topics
- Health Sciences › Medicine › Hematology › Multiple Myeloma Research and Treatments
- Life Sciences › Immunology and Microbiology › Immunology › Monoclonal and Polyclonal Antibodies Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Degradation and Inhibitors
- Keywords
- teclistamab, relapsed/refractory multiple myeloma, bispecific T-cell engagers, overall response rate, minimal residual disease negativity, progression-free survival, cytokine release syndrome, neurotoxicity, dose-limiting toxicity, subcutaneous administration, immunotherapy safety and efficacy
- MeSH terms
- Antineoplastic Agents, Immunological, Antineoplastic Agents, Antineoplastic Combined Chemotherapy Protocols, Humans, Injections, Subcutaneous, Multiple Myeloma, Neoplasm Recurrence, Local, Recurrence, T-Lymphocytes, CD3 Complex, Antibodies, Bispecific, B-Cell Maturation Antigen, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-10-12, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-12 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
